One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Both the U.S. label and UCSF use indexed eGFR for this combination. Their printed renal-band boundaries differ: the UCSF bands overlap at 30 and place 50 in a different printed band. Retain the selected source boundary explicitly; do not treat an overlap as an instruction to combine regimens.
Both tables use indexed eGFR, but the label assigns exactly 50 to its full-dose band, whereas UCSF prints >50 and 30-50. UCSF also prints overlapping bands at exactly 30. The dialysis and indication scopes are separately stated.
What to reconcile: Do not silently round an estimate, substitute unindexed CrCl, average doses, or combine one source's band with another interval. Clarify boundary cases with the applicable label and institutional antimicrobial team.
Open this note and its source referencesFor adult complicated UTI including pyelonephritis, infuse each dose over 3 hours; label treatment duration is up to 14 days.
| MDRD eGFR (mL/min/1.73 m2) | Total combination dose | Interval |
|---|---|---|
| >=50 | 4 g (2 g meropenem + 2 g vaborbactam) | Every 8 hours |
| 30-49 | 2 g (1 g + 1 g) | Every 8 hours |
| 15-29 | 2 g (1 g + 1 g) | Every 12 hours |
| <15 | 1 g (0.5 g + 0.5 g) | Every 12 hours |
Give renal-adjusted doses after HD. The label uses indexed MDRD eGFR, not unindexed Cockcroft-Gault CrCl. Do not apply a meropenem-alone regimen to this combination.
RDM30-069-meropenem-vaborbactam-1 · Source locator: VABOMERE - adult U.S. label; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=meropenem-vaborbactam&s1=RDM30-069-meropenem-vaborbactam&h1=58d4f015e0ff7a542a06f75639756767326a557d4e7b4fff95b33957f04b775d